Tolerability and Efficacy of Deucravacitinib in the Treatment of Refractory Psoriasis

Key Points

• The aim is to assess the tolerability and efficacy of deucravacitinib for patients with refractory psoriasis.
• Randomized trial design with participants having refractory psoriasis.
• Assessment of tolerability and efficacy outcomes.
• Use of appropriate clinical measures to evaluate treatment response.
• Deucravacitinib demonstrates a significant improvement in psoriasis symptoms compared to baseline.
• Participants show enhanced tolerability with fewer adverse effects.
• Positive response rates markedly exceed traditional treatment benchmarks.